BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37531016)

  • 1. Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy.
    Dux J; Habibi M; Malik H; Jacobs L; Wright PA; Lange J; Camp M; O'Donnell M; Sun B; Tran HT; Euhus D
    Breast Cancer Res Treat; 2023 Nov; 202(2):267-273. PubMed ID: 37531016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).
    Park Y; Shin YS; Kim K; Shin KH; Chang JH; Kim SS; Jung JH; Park W; Kim H; Kim YB; Ahn SJ; Kim M; Kim JH; Cha HJ; Kim TG; Park HJ; Lee SY
    Eur J Surg Oncol; 2023 Mar; 49(3):589-596. PubMed ID: 36470801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored axillary surgery - A novel concept for clinically node positive breast cancer.
    Heidinger M; Knauer M; Tausch C; Weber WP
    Breast; 2023 Jun; 69():281-289. PubMed ID: 36922305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.
    Weber WP; Matrai Z; Hayoz S; Tausch C; Henke G; Zimmermann F; Montagna G; Fitzal F; Gnant M; Ruhstaller T; Muenst S; Mueller A; Lelièvre L; Heil J; Knauer M; Egle D; Sávolt Á; Heidinger M; Kurzeder C; ; Zwahlen DR; Gruber G; Ackerknecht M; Kuemmel S; Bjelic-Radisic V; Smanykó V; Vrieling C; Satler R; Hagen D; Becciolini C; Bucher S; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Fansa H; Hager C; Reisenberger K; Singer CF; Loibl S; Winkler J; Lam GT; Fehr MK; Kohlik M; Clerc K; Ostapenko V; Maggi N; Schulz A; Andreozzi M; Goldschmidt M; Saccilotto R; Markellou P
    JAMA Surg; 2023 Oct; 158(10):1013-1021. PubMed ID: 37466971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
    Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
    Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
    Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
    J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Weber WP; Heidinger M; Hayoz S; Matrai Z; Tausch C; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Montagna G; Andreozzi M; Goldschmidt M; Schulz A; Mueller A; Ackerknecht M; Tampaki EC; Bjelic-Radisic V; Kurzeder C; Sávolt Á; Smanykó V; Hagen D; Müller DJ; Gnant M; Loibl S; Fitzal F; Markellou P; Bekes I; Egle D; Heil J; Knauer M
    Ann Surg Oncol; 2024 Jan; 31(1):344-355. PubMed ID: 37903951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer: a National Cancer Database analysis.
    Cocco D; Shah C; Wei W; Wilkerson A; Grobmyer SR; Al-Hilli Z
    Br J Surg; 2022 Nov; 109(12):1293-1299. PubMed ID: 36066266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
    Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M
    JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis.
    Petousis S; Christidis P; Margioula-Siarkou C; Liberis A; Vavoulidis E; Margioula-Siarkou G; Vatopoulou A; Papanikolaou A; Mavromatidis G; Dinas K
    Arch Gynecol Obstet; 2022 Oct; 306(4):1221-1234. PubMed ID: 35249123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
    Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
    Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Damin AP; Zancan M; Melo MP; Biazus JV
    Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Weber WP; Matrai Z; Hayoz S; Tausch C; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Seiler S; Maddox C; Ruhstaller T; Muenst S; Ackerknecht M; Kuemmel S; Bjelic-Radisic V; Kurzeder C; Újhelyi M; Vrieling C; Satler R; Meyer I; Becciolini C; Bucher S; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Dubsky P; Exner R; Fansa H; Hager C; Reisenberger K; Singer CF; Reitsamer R; Reinisch M; Winkler J; Lam GT; Fehr MK; Naydina T; Kohlik M; Clerc K; Ostapenko V; Fitzal F; Nussbaumer R; Maggi N; Schulz A; Markellou P; Lelièvre L; Egle D; Heil J; Knauer M
    Breast; 2021 Dec; 60():98-110. PubMed ID: 34555676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.